The Melbourne Children’s Campus is seeing an increase in the number of clinical trials of gene therapies, especially in vivo viral vector therapies. With some of these therapies now approved by the TGA, there is an expectation by families that these therapies will be available at the Children’s.
“Vaccine inequity – The world is on the brink of a catastrophic moral failure, and the price of this failure will be paid with lives and livelihoods in the world’s poorest countries.”
Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
The availability of effective vaccines for the prevention of covid-19 has led to an unseemly competition as countries rushed to sign deals with manufacturers, often outbidding each other for access, to the exclusion of poorer countries. In high income countries 60% of people have received at least one dose of Covid vaccine, while in low income countries the figure is 3%.
We have a National Roadmap, which includes COVID-19 vaccine coverage targets for the easing of restrictions. But how do children and adolescents fit into this, with regard the direct and indirect effects of Delta on their health and well-being?
Reproductive carrier screening has been possible since the 1970s. Initially conducted by testing of blood analytes for carrier status for haemoglobinopathies and Tay Sachs disease, screening for an ever increasing number of conditions became possible by genetic testing from the late 1980s. The advent of genomic sequencing means that it is now possible to screen over 1000 genes, a process called expanded carrier screening.
Mental Health is an issue of growing concern across the community. This has been amplified through the COVID-19 pandemic. Child mental health is also an ongoing priority for the Melbourne Children’s Campus (MCC) and its three partners. The RCH treats many vulnerable patient groups (e.g., children with chronic illness, neurodevelopmental disorders, psychosocial challenges) with elevated risk of psychological and mental health difficulties. This extends across our inpatient and outpatient services and into the community. Despite this, mental health services can be fragmented and difficult to access.
Tuberculosis is a major cause of child morbidity and mortality globally. Young children are at particular risk of severe and disseminated disease following exposure to a person with tuberculosis. Public health and clinical services, including in Victoria, focus on early detection and treatment of both disease and infection. There have been recent developments that potentially strengthen and decentralise services for tuberculosis.
We are unleashing the power of data to improve child health. The first such Centre in Australia is a hive of potential and ideas, realising the shared vision of our campus partners. We are using data to advance and humanise many different perspectives of paediatric patient care.
Genetic conditions are the leading cause of death in children in high-income countries. Accurate and timely diagnosis is critical for being able to provide prognostic information and guide treatment, yet often takes many years.
Too often research evidence fails to inform practice or policy, and opportunities to improve children’s health and wellbeing are lost. The Melbourne Children’s Knowledge Translation and Research Impact Project, funded by the RCH Foundation, seeks to better understand campus KT and impact needs, and has developed and piloted strategies to advance knowledge translation, implementation and research impact.
Medulloblastoma is the most common malignant brain tumour of childhood. Despite multidisciplinary therapies offered by neurosurgery, radiation oncology and paediatric oncology through cooperative group clinical trials, there are significant late effects of therapy, including but not limited to neuroendocrine deficits, neurocognitive impairment and second malignant neoplasms
